Impact of sphingosine 1-phosphate modulation on immune outcomes

Neurology

Volumn 76, Issue 8 SUPPL. 3, 2011, Pages

  Pinschewer, Daniel D ^a   Brinkmann, Volker ^b   Merkler, Doron ^a,c  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD; PLACEBO; SPHINGOSINE 1 PHOSPHATE;

BRONCHITIS; CANCER RISK; DEMYELINATION; HERPES SIMPLEX ENCEPHALITIS; HERPES VIRUS INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LONG TERM CARE; LOWER RESPIRATORY TRACT INFECTION; LYMPHOCYTE ACTIVATION; MEMORY T LYMPHOCYTE; MULTIPLE SCLEROSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; VIRUS INFECTION;

EID: 79952015024     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31820d9596     Document Type: Article

References (38)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343:938-952.
2. Isaacs A, Lindenmann J. Virus interference. I. the interferon. Proc R Soc Lond B Biol Sci 1957;147:258-267.
3. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004;427:355-360. (Pubitemid 38133663)
4. Manz RA, Arce S, Cassese G, Hauser AE, Hiepe F, Radbruch A. Humoral immunity and long-lived plasma cells. Curr Opin Immunol 2002;14:517-521. (Pubitemid 34671256)
5. Winkelstein JA, Marino MC, Lederman HM, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine 2006;85:193-202. (Pubitemid 44107177)
6. Sanna PP, Burton DR. Role of antibodies in controlling viral disease: lessons from experiments of nature and gene knockouts. J Virol 2000;74:9813-9817.
7. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010;17:1055-1065.
8. Theil D, Derfuss T, Paripovic I, et al. Latent herpesvirus infection in human trigeminal ganglia causes chronic immune response. Am J Pathol 2003;163:2179-2184. (Pubitemid 37466462)
9. Horwitz MS, Bradley LM, Harbertson J, Krahl T, Lee J, Sarvetnick N. Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat Med 1998;4:781-785. (Pubitemid 28331018)
10. Miller SD, Vanderlugt CL, Begolka WS, et al. Epitope spreading leads to myelin-specific autoimmune responses in SJL mice chronically infected with Theiler's virus. J Neurovirol 1997;3(suppl 1):S62-S65. (Pubitemid 27232313)
11. Fujinami RS, Oldstone MB. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science 1985;230:1043-1045. (Pubitemid 16192692)
12. Merkler D, Horvath E, Bruck W, Zinkernagel RM, Del la Torre JC, Pinschewer DD. "Viral deja vu" elicits organ-specific immune disease independent of reactivity to self. J Clin Invest 2006;116:1254-1263.
13. Allende ML, Dreier JL, Mandala S, Proia RL. Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration J Biol Chem 2004;279:15396-15401.
14. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002;277:21453-21457. (Pubitemid 34952287)
15. Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 2004;4:1019-1025. (Pubitemid 38868590)
16. Pham TH, Okada T, Matloubian M, Lo CG, Cyster JG. S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. Immunity 2008;28:122-133.
17. Graler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 2004;18:551-553.
18. Pham TH, Baluk P, Xu Y, et al. Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning. J Exp Med 2010;207:17-27.
19. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002;296:346-349. (Pubitemid 34303689)
20. Thangada S, Khanna KM, Blaho VA, et al. Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics. J Exp Med 2010;207:1475-1483.
21. Grigorova IL, Schwab SR, Phan TG, Pham TH, Okada T, Cyster JG. Cortical sinus probing, S1P1-dependent entry and flow-based capture of egressing T cells Nat Immunol 2009;10:58-65.
22. Wehrli N, Legler DF, Finke D, et al. Changing responsiveness to chemokines allows medullary plasmablasts to leave lymph nodes. Eur J Immunol 2001;31:609-616. (Pubitemid 32166616)
23. Wei SH, Rosen H, Matheu MP, et al. Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. Nat Immunol 2005;6:1228-1235. (Pubitemid 43045634)
24. Sanna MG, Wang SK, Gonzalez-Cabrera PJ, et al. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat Chem Biol 2006;2:434-441. (Pubitemid 44114922)
25. Pappu R, Schwab SR, Cornelissen I, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 2007;316:295-298. (Pubitemid 46633109)
26. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004;22:745-763. (Pubitemid 38680440)
27. Metzler B, Gfeller P, Wieczorek G, et al. Modulation of T cell homeostasis and alloreactivity under continuous FTY720 exposure. Int Immunol 2008;20:633-644. (Pubitemid 351619233)
28. Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008;71:1261-1267.
29. Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010;9:883-897.
30. Kivisakk P, Mahad DJ, Callahan MK, et al. Expression of CCR7 in multiple sclerosis: implications for CNS immunity. Ann Neurol 2004;55:627-638. (Pubitemid 38544322)
31. Fujino M, Funeshima N, Kitazawa Y, et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 2003;305:70-77. (Pubitemid 36378136)
32. Appay V, van Lier RA, Sallusto F, Roederer M. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A 2008;73:975-983.
33. Pinschewer DD, Ochsenbein AF, Odermatt B, Brinkmann V, Hengartner H, Zinkernagel RM. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol 2000;164:5761-5770. (Pubitemid 30389819)
34. Bartholomäus I, Schläger C, Brinkmann V, Wekerle H, Flügel A. Intravital 2-photon imaging of encephalitogenic effector cells during fingolimod (FTY720) treatment of experimental autoimmune encephalomyelitis. Mult Scler 2008;14:S30.
35. Kursar M, Janner N, Pfeffer K, Brinkmann V, Kaufmann SH, Mittrucker HW. Requirement of secondary lymphoid tissues for the induction of primary and secondary T cell responses against Listeria monocytogenes. Eur J Immunol 2008;38:127-138.
36. Connor LM, Harvie MC, Rich FJ, et al. A key role for lung-resident memory lymphocytes in protective immune responses after BCG vaccination. Eur J Immunol 2010;40:2482-2492.
37. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-415.
38. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.